TORONTO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company announced the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of TALTZ® (ixekizumab) versus Humira® (adalimumab) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback